hackint0sh/New-Dataset huggingface dataset:
* Participants will walk on the gym floor or an adjusted treadmill for at least 15 to 20 minutes during each session. Participants will be instructed to use the mirror for feedback and achieve the target modified gait procedure. However, it will be emphasised gait modification procedures exhibited at baseline pain and function, and then at the end of the trial, it will focus on subjects' acceptability. primaryPurpose: OTHER masking: NONE count: 17 type: ACTUAL name: Lateral Wedge insole measure: Pain level measure: Western Ontario and McMaster Universities Arthritis Index-total measure: Likert scale measure: Likert scale sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: King Faisal Specialist Hospital & Research Centre city: Jeddah state: Western country: Saudi Arabia lat: 21.54238 lon: 39.19797 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-01-04 uploadDate: 2024-03-07T05:51 filename: Prot_000.pdf size: 234397 hasResults: False
nctId: NCT06306066 id: 2015/962-31 briefTitle: Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome overallStatus: COMPLETED date: 2015-09-02 date: 2021-06-07 date: 2022-12-28 date: 2024-03-12 date: 2024-03-12 name: Karolinska Institutet class: OTHER name: Abbott briefSummary: Patients scheduled for elective coronary angiography due to chronic coronary syndrome are recruited at admission to hospital before the coronary anatomy is known. Immediately after coronary angiography measures thermo-dilution derived flow indices are obtained in the left left anterior descending artery (LAD). The patients are followed through telephone-calls and medical records at 1 and 2 years after inclusion and at completion of the study. The hypothesis is that elevated index of microcirculatory resistance (IMR),(\>25) is associated with all-cause death, myocardial infarction (MI) and hospitalization due to congestive heart failure (CHF).
The primary analysis is the relationship between IMR and the composite outcome all-cause death, MI and hospitalization due to CHF. conditions: Coronary Artery Disease conditions: Microvascular Angina conditions: Coronary Microvascular Dysfunction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 505 type: ACTUAL measure: Rate of all-cause mortality, MI and/or hospitalization due to CHF measure: Rate of all-cause mortality measure: Rate of hospitalization due to CHF. measure: Rate of all-cause mortality and/or MI measure: Rate of MI measure: Rate of stroke measure: Rate of ischemic stroke measure: Rate of unscheduled revascularization sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Danderyd University Hospital and Karolinska Institutet Danderyds University Hospital (KI DS) city: Stockholm zip: 182 88 country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06306040 id: Analgesia effect as on EA briefTitle: Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2024-11-03 date: 2025-01-30 date: 2024-03-12 date: 2024-03-12 name: Assiut University class: OTHER briefSummary: • Primary outcome: Measure The incidence of EA in children undergoing to hypospadias repair under general anesthesia is considered using Pediatric Anesthesia Emergence Delirium (PAED) scales.
* Therefore, we designed a prospective, randomized, double-blind, single center study to investigate whether nalbuphine and/or magnesium sulphate can prevent EA after hypospadias repair in children under general anesthesia. In addition, the characteristics of anesthesia recovery and the incidence of adverse effects will also be evaluated in this study. Post-operative extubating time, interaction time, open eye time and emergence time. incidence of post-operative vomiting (PONV), laryngospasm, breath-holding, coughing, oxygen desaturation, and cardiac arrhythmias.
* Group N (Nalbuphine group n=35 ): 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery primaryPurpose: PREVENTION masking: SINGLE maskingDescription: * Group C (Control group n=35 ): 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery
* Group N (Nalbuphine group n=35 ): 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery whoMasked: PARTICIPANT count: 105 type: ESTIMATED name: Nalbuphine Versus Magnesium Sulfate measure: compare between analgesia effect on pediatric patient sex: MALE minimumAge: 3 Years maximumAge: 7 Years stdAges: CHILD hasResults: False
nctId: NCT06306014 id: 69HCL22_980 id: 2023-506232-32-00 type: OTHER domain: EU CT Number briefTitle: Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients acronym: LIVEDIFF overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-01-01 date: 2027-01-01 date: 2024-03-12 date: 2024-03-12 name: Hospices Civils de Lyon class: OTHER name: Exeliom Biosciences briefSummary: Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.
Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.
Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.
nctId: NCT06306001 id: IIRP-2023-1820/F1 briefTitle: Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-03-14 date: 2027-02 date: 2024-03-12 date: 2024-03-12 name: Post Graduate Institute of Medical Education and Research, Chandigarh class: OTHER briefSummary: Preterm infants (born at less than 37 weeks of pregnancy) sometimes develop a serious blood infection leading to low blood pressure, which does not respond to saline or to the standard medicines for increasing blood pressure, such as dopamine and epinephrine. The goal of this research study is to compare the effect of giving an injectable medicine called Methylene blue (MB) versus not giving MB to such preterm infants who are unresponsive to standard treatment. The main questions that this study aims to answer is:
4. Whether treatment with MB improves heart function as measured by echocardiography at 24 and 48 hours. conditions: Neonatal Sepsis conditions: Shock, Septic studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Subjects will be randomly allocated to an intervention arm and a placebo arm. The 2 arms of the trial will run concurrently. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The random allocation will be concealed using serially numbered opaque sealed envelopes. After opening the envelope, a research nurse will administer a bolus of the study drug or placebo behind a screen, shielded from other staff. The infusion will be drawn up in an opaque syringe by the research nurse and infused through an intravenous tubing covered completely with aluminum foil. The research nurses will not be masked to the study drug. The parents of the subject, the regular staff nurses and doctors working in the unit and the project coordinator will be masked. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 130 type: ESTIMATED name: Methylene Blue name: Placebo measure: All-cause mortality within 7 days after randomization measure: Time taken to achieve therapeutic end-points within 7 days after randomization measure: Time taken to stop all inotrope/vasopressor treatment within 7 days after randomisation measure: Echocardiographic fractional shortening at 24 hour after randomization measure: Left ventricular end-diastolic diameter (LVEDD) by echocardiography at 24 hour after randomization measure: Left ventricular end-systolic diameter (LVESD) by echocardiography at 24 hour after randomization measure: Aortic diameter by echocardiography at 24 hour after randomization measure: Velocity time integral (LVI) by echocardiography at 24 hours after randomization measure: Echocardiographic fractional shortening at 48 hour after randomization measure: Left ventricular end-diastolic diameter (LVEDD) on echocardiography at 48 hour after randomization measure: Left ventricular end-systolic diameter (LVESD) by echocardiography at 48 hour after randomization measure: Aortic diameter by echocardiography at 48 hour after randomization measure: Velocity time integral (LVI) by echocardiography at 48 hours after randomization measure: Time taken to stop vasopressor treatment measure: Mortality during hospital stay measure: Serious adverse effects measure: Septic shock-related mortality sex: ALL minimumAge: 0 Days maximumAge: 28 Days stdAges: CHILD facility: Post Graduate Institute of Medical Education and Research (PGIMER) city: Chandigarh zip: 160012 country: India lat: 30.73629 lon: 76.7884 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-01-22 uploadDate: 2024-03-01T05:10 filename: Prot_SAP_000.pdf size: 210368 hasResults: False
nctId: NCT06305988 id: LYG2023021 briefTitle: Neuroregulatory Effect and Mechanism of tDCS on Medial Prefrontal Cortex in ASD overallStatus: RECRUITING date: 2023-08-01 date: 2024-07-31 date: 2024-07-31 date: 2024-03-12 date: 2024-03-15 name: Jian-Jun Ou class: OTHER briefSummary: In this proposed study, a transcranial direct current stimulator is used to intervene in the medial prefrontal cortex of children with autism, and the efficacy of this intervention method is evaluated, as well as the internal mechanism of Autism Spectrum Disorders' intervention is discussed. conditions: ASD studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Transcranial direct current stimulation measure: Autism assessment assessment index measure: EEG physiological detection index measure: Social Communication Changes index measure: Stereotyped behavior index measure: Sensory index measure: Abnormal behavior indicator measure: Sleep index measure: Plasma Metabolite Levels Assessment measure: Safety evaluation SAFTEE indicator sex: ALL minimumAge: 4 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Department of Psychiatry, Xiangya Second Hospital, Central South University status: RECRUITING city: Changsha state: Hunan zip: 410000 country: China name: Jianjun Ou, doctor role: CONTACT phone: 17775861486 email: oujianjun@csu.edu.cn lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06305975 id: STUDY00003169 briefTitle: Blunt Fascial vs. Veress Needle Peritoneal Entry in Laparoscopic Gynecologic Surgery acronym: BluntFascial overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03-01 date: 2025-03-01 date: 2024-03-12 date: 2024-03-12 name: Cedars-Sinai Medical Center class: OTHER briefSummary: This study aims to investigate the effect of two peritoneal entry techniques on intraoperative and post-operative outcomes among patients undergoing laparoscopic surgery with a minimally invasive gynecologic surgeon. Patients will be randomized to either blunt fascial or veress needle peritoneal entry. Insufflation times, failed entries, complications and post-operative pain scores will be collected.
Secondary Objectives: To evaluate the surgical outcomes and patients pain scores according to peritoneal entry technique. conditions: Laparoscopic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Blunt fascial abdominal entry name: Veress needle abdominal entry measure: Insufflation time measure: Success upon peritoneal entry measure: Intraoperative complications measure: Postoperative complications measure: Patients pain scores measure: Analgesics use measure: Length of hospital stay sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305962 id: 177Lu-RAD204.2023.0001 briefTitle: 177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer overallStatus: RECRUITING date: 2024-03 date: 2025-07 date: 2025-10 date: 2024-03-12 date: 2024-03-26 name: Radiopharm Theranostics, Ltd class: INDUSTRY briefSummary: This is a first-in-human, open-label study consisting of a Screening Period, an Imaging Period, and a Treatment Period in eligible non-small lung cancer patients who are positive for the biomarker PDL-1. The Screening period lasts up to 4 weeks. The Phase 0 (Imaging Period) is used to determine if patient's tumor(s) are still positive for the biomarker, as well as radiation dosimetry with low dose 177Lu-RAD204im (for a period of up to 2 weeks following the first injection of 177Lu-RAD204im), to assess the safety of the drug. Following the 2 week safety assessment, the subject is eligible to enter Phase I (Treatment Period) with gradual dose increases of 177Lu-RAD204tr. The Treatment Period lasts up to 3 cycles every 6 weeks, with additional extension to a maximum study dose interval of 12 weeks to be approved on a case-by-case basis in discussion with study Sponsor. During the Treatment Period, subjects will be assessed for both safety and treatment response using conventional images and clinical laboratory tests. conditions: PDL1 Gene Mutation conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 23 type: ESTIMATED name: 177Lu-RAD204 measure: Time Activity Curves (TACs) measure: Radiation dosimetry of Lu177-RAD204im measure: Pharmacokinetics of 177Lu-RAD204im measure: Biokinetics of 177Lu-RAD204im measure: Safety and tolerability of 177Lu-RAD204tr measure: Recommended dose(s) of 177Lu-RAD204tr for future exploration measure: Safety and tolerability of a single dose of 177Lu-RAD204im measure: Recommended dose(s) of 177Lu-RAD204im for future exploration measure: Preliminary antitumor activity of 177Lu-RAD204tr measure: Radiation dosimetry of 177Lu-RAD204tr measure: Level of agreement between 177Lu-RAD204im and standard of care imaging measure: Effect of 177Lu-RAD204im and 177Lu-RAD204tr on tumor markers sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Princess Alexandra Hospital status: RECRUITING city: Woolloongabba state: Queensland zip: 4102 country: Australia name: Kenneth O'Byrne, MD role: CONTACT phone: +610449091958 email: kenneth.obyrne@health.qld.gov.au lat: -27.48855 lon: 153.03655 facility: Hollywood Private Hospital status: RECRUITING city: Nedlands state: Western Australia zip: 6009 country: Australia name: Joe Cardaci, MD role: CONTACT phone: 0893862844 email: jcardaci@dni.com.au lat: -31.98184 lon: 115.8073 hasResults: False
nctId: NCT06305949 id: XC23DDDS0098 briefTitle: Clinical Trial on the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Swallowing Function in Patients With Post-Stroke Dysphagia overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-07-31 date: 2025-12-31 date: 2024-03-12 date: 2024-03-12 name: NEUROPHET class: INDUSTRY name: Bucheon St. Mary's Hospital name: Saint Vincent's Hospital, Korea name: National Traffic Injury Rehabilitation Hospital name: Pusan National University Yangsan Hospital briefSummary: The goal of this clinical trial is to evaluate whether the application of optimized transcranial direct current stimulation is more effective compared to sham stimulation for temporary improvement of swallowing function in patients with post-stroke dysphagia. conditions: Deglutition Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Personalized transcranial Direct Current Stimulation measure: Functional Oral Intake Scale (FOIS) measure: Penetration-aspiration Scale (PAS) measure: Functional Oral Intake Scale (FOIS) measure: Penetration-aspiration Scale (PAS) measure: Videofluoroscopic Dysphagia Scale (VDS) measure: Korean Mann Assessment of Swallowing Ability (K-MASA) measure: Speech Mechanism Screening Test (SMST) measure: Urimal Test of Articulation and Phonology (U-TAP) measure: modified Rankin Scale (mRS) measure: Gugging Swallowing Screen measure: Eating Assessment Tool-10 (EAT-10) measure: Iowa Oral Performance Instrument (IOPI) measure: Motor-Evoked Potential (MEP) measure: Grade, Roughness, Breathiness, Asthenia and Strain scale(GRBAS scale) measure: Respiratory muscle strength measure: Peak cough flow sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305936 id: PLATE H-23042292 briefTitle: Feasibility Study: Plant Based Diet to Patients With Rheumatoid Arthritis acronym: PLATE overallStatus: RECRUITING date: 2024-02-15 date: 2024-07-31 date: 2024-12-31 date: 2024-03-12 date: 2024-03-15 name: Bispebjerg Hospital class: OTHER name: Glostrup University Hospital, Copenhagen briefSummary: In this feasibility study, our primary goal is to assess the practicality of implementing a plant-based food diet intervention for individuals with rheumatoid arthritis (RA). The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. This comprehensive investigation covers the testing of recruitment procedures, randomization, intervention elements, outcome assessments, and participant retention.
Adopting a daily plant-based diet involves introducing several new plant-based foods and making adjustments to the existing diets of patients with RA. Consequently, the feasibility study will also aim to explore the acceptability of the intervention and whether a full-scale RCT is practically possible. conditions: Rheumatoid Arthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised feasibility study of an intervention group, receiving 100% plant-based diet and a control group primaryPurpose: OTHER masking: DOUBLE maskingDescription: Not possible to blind participants and study staff delivering the intervention to allocation status, whereas all outcome data is planned to be collected by blinded outcome assessors. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Intervention with 100% plant-based diet measure: Evaluation of Feasibility and Intervention Fidelity in Implementing a Plant-Based Food Diet Intervention - Evaluating the feasibilty of included objectively measured outcomes and self-administered questionnaires measure: Evaluation of Study Acceptance measure: Recruitment measure: Retention measure: Intervention adherence measure: Disease Activity Score (DAS28) measure: Fatigue: Bristol Rheumatoid Arthritis Fatigue (BRAF MDQ) measure: Pain (VAS) measure: Sleep measure: Anxiety/depression measure: Physical function measure: Impact of rheumatoid arthritis (RA) measure: The EuroQuality of Life (EQ-5D) measure: Height measure: Weight measure: Waist- and hip circumference measure: Disease activity measure: Body composition measure: Quantification of tender and swollen joints measure: C-reactive Protein (CRP) measure: Hemoglobin measure: Leukocytes measure: Thrombocytes measure: Hemoglobin (HbA1c) measure: D-vitamin measure: Low-density lipoprotein (LDL) measure: High-density lipoprotein (HDL) measure: Triglyceride measure: Total cholesterol sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Clinical Research and Prevention, BispebjergH status: ACTIVE_NOT_RECRUITING city: Frederiksberg zip: DK 2000 country: Denmark lat: 55.67938 lon: 12.53463 facility: The Department of Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Glostrup status: RECRUITING city: Glostrup zip: 2600 country: Denmark name: Tanja Thomsen, Ph.D. role: CONTACT phone: +4538163107 email: tanja.thomsen@regionh.dkdkTanja.thomsen@regionh.dk name: Kamille Torp, Ph.D. role: CONTACT phone: +4538163113 email: kamille.almer.bernsdorf.torp@regionh.dk name: Bente Appel Esbensen, Ph.D. role: SUB_INVESTIGATOR lat: 55.6666 lon: 12.40377 hasResults: False
nctId: NCT06305923 id: RNN/275/21/KE id: 503/3-066-02/503-31-001 type: OTHER_GRANT domain: Medical University of Lodz briefTitle: The Efficacy of a Cosmetic Preparation Containing Sheep Colostrum on Mature Skin acronym: COLMATSKIN overallStatus: COMPLETED date: 2022-03-01 date: 2022-06-30 date: 2022-07-31 date: 2024-03-12 date: 2024-03-12 name: Medical University of Lodz class: OTHER briefSummary: The goal of this clinical trial is to learn about colostrum as a cosmetic in mature skin. . The aim of the study was to examine the effect of a cosmetic preparation containing sheep colostrum on skin with signs of aging in mature women Participants will be given the creams and asked to apply one -two doses in the evening after nighttime facial cleaning. They were also asked to use sunscreens during the day. During the first visit and after eight weeks of everyday use of the tested cream, the skin parameters will be measured three times on both cheeks, and the results were averaged.
Participants will be enrolled to the colostrum cream or base cream groups and will not be informed which group they belonged to. conditions: Skin Aging studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 52 type: ACTUAL name: colostrum cream name: placebo cream measure: hydration measure: transepidermal water loss measure: erythema and melanin content measure: sebum measure: firmness of the skin measure: firmness of the skin sex: FEMALE minimumAge: 40 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of Lodz city: Lodz zip: 90-419 country: Poland lat: 51.75 lon: 19.46667 hasResults: False